Macquarie Group
LSTA icon

Macquarie Group’s Lisata Therapeutics LSTA Stock Holding History

Macquarie Group’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-87
Closed -$5K – 1876
2018
Q4 		$5K Sell
87
-100
-53% -$6.95K ﹤0.01% 2103
2018
Q3 		$17K Sell
187
-796
-81% -$65.3K ﹤0.01% 1927
2018
Q2 		$95K Sell
983
-1,674
-63% -$118K ﹤0.01% 1857
2018
Q1 		$233K Buy
2,657
+664
+33% +$46K ﹤0.01% 1656
2017
Q4 		$105K Buy
1,993
+1,520
+321% +$76.4K ﹤0.01% 1891
2017
Q3 		$25K Buy
+473
New +$28.7K ﹤0.01% 2072

Other funds holding LSTA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TFO
Tarbox Family Office Newport Beach, California $616M AUM 18.34% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

Macquarie Group's LSTA Position: Q1 2019 in Review

Macquarie Group sold out of Lisata Therapeutics (LSTA) in Q1 2019, closing a stake of 87 shares — an estimated $5K sold.

Macquarie Group first reported a position in LSTA in Q3 2017 and held it in 6 quarters. The position peaked at $233K in Q1 2018. 28 funds tracked by Wall St. Rank hold LSTA as of Q1 2019.

  • Macquarie Group reported no remaining Lisata Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Macquarie Group sold 87 Lisata Therapeutics shares in Q1 2019, an estimated $5K.
  • Macquarie Group first reported a position in Lisata Therapeutics in Q3 2017 and held it in 6 quarters.
  • Macquarie Group's Lisata Therapeutics position peaked at $233K in Q1 2018.
  • 28 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2019.

Based on Macquarie Group's 13F filing for Q1 2019, filed 15 May 2019.